CAR T-Cell Therapy Shows Consistent Safety and Pharmacokinetics in NHL
April 12th 2021Scott R. Solomon, MD, discusses the adverse events and pharmacokinetics of lisocabtagene maraleucel in 12 patients with relapsed/refractory large B-cell non-Hodgkin lymphoma who had previously received anti-CD19 therapy.